SCHEMBL16635960

SCHEMBL16635960

COC(=O)C1CC(=O)CCC1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.39
CYP1A2 P05177 2/20 0.37
HIF1A Q16665 1/20 0.37
GAA P10253 1/20 0.36
PPM1B O75688 1/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36
TSHR P16473 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
BRD4 O60885 1/20 0.35
MMP2 P08253 1/20 0.35
ANPEP P15144 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SLC6A2 P23975 3/20 0.34
SLC6A4 P31645 3/20 0.34
SLC6A3 Q01959 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172703 1.00 THRB (0.39) THRBCYP1A2HIF1AGAAPPM1B
SCHEMBL16617840 0.91 THRB (0.42) THRBCYP1A2HIF1ATSHRHTT
SCHEMBL21294835 0.91 THRB (0.42) THRBCYP1A2HIF1ATSHRHTT
SCHEMBL21312252 0.91 THRB (0.42) THRBCYP1A2HIF1ATSHRHTT
SCHEMBL16617853 0.91 THRB (0.42) THRBCYP1A2HIF1ATSHRHTT
SCHEMBL12294236 0.85 BRD4 (0.39) CYP1A2HIF1APPM1BPTPN1PPP1CC
SCHEMBL9110600 0.85 BRD4 (0.39) CYP1A2HIF1APPM1BPTPN1PPP1CC
SCHEMBL3056179 0.85 BRD4 (0.39) CYP1A2HIF1APPM1BPTPN1PPP1CC
SCHEMBL18595954 0.85 BRD4 (0.39) CYP1A2HIF1APPM1BPTPN1PPP1CC
SCHEMBL9110589 0.85 BRD4 (0.39) CYP1A2HIF1APPM1BPTPN1PPP1CC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ THRB 2781/4885CYP1A2 4535/4885HIF1A 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.